Abstract: Methods and compositions for treatment of impaired visual acuity caused by presbyopia, hyperopia, or astigmatism and methods and compositions for enhancing contrast sensitivity and stereopsis are disclosed. In general, topical composition comprising from about 0.05 to 10 wt % of a methylated xanthine and from about 1 to 10 wt % of an ophthalmic miotic agent are applied to the outer surface of at least one eyelid of a subject.

Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.

Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.

Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.

Abstract: Cosmetic compositions comprising therapeutic agents for the treatment of various eye conditions and methods of use are described. In particular, the invention provides cosmetic compositions comprising ophthalmic therapeutic agents in combination with a muscle fasciculating agent for application to the outer surface of the upper eyelid, perimeter of the eyelid and/or eyelashes thereby causing transfer of the therapeutic agents into the vascular network within the eyelid for delivery into all parts of the eye, including the posterior segments of the eye, the eyelid glands, conjuctiva and periocular tissue.

Abstract: The present invention provides a biocompatible Conductive Keratoplasty probe guide device having an arcuate member and at least one orifice capable of allowing the probe to be inserted through the orifice. Also, the present invention teaches methods related to guiding a CK probe through this probe guide device.

Abstract: The present invention provides a biocompatible Conductive Keratoplasty probe guide device having an arcuate member and at least one orifice capable of allowing the probe to be inserted through the orifice. Also, the present invention teaches methods related to guiding a CK probe through this probe guide device.